Skip to content
Research Article Open access CC BY 4.0

Virological Follow-up of Adults Living with HIV on Dolutegravir in an Approved Treatment Center in Douala (Cameroon)

Ngondi Dalle Grâce, Boma Bang Luc Vital, Essola Josiane, Ndjengue Nson Louis Sides, Medi Sike Christiane, Nke Ateba Gisèle, Penda Ida Calixte, Okalla Ebongue Cécile, Nda Mefoo Jean Pierre

Journal of Advances in Biology & Biotechnology · pp. 1–8 · Published 2 Aug 2023

10.9734/jabb/2023/v26i6637

Abstract

Background: Human immunodeficiency virus infection constitutes one of the greatest contemporary human pandemics, lethal in the absence of treatment. WHO 2018 recommendations have placed Dolutegravir-based treatment as first-line treatment, particularly in resource-limited countries. The aim of this work was to study the evolution of virological parameters in people undergoing treatment with this molecule. Methodology: This was an analytical cross-sectional study of people aged 25 and over, received since January 2015 at the Approved Treatment center of Laquintinie Hospital in Douala (Cameroon). After plasma collection and centrifugation, viral load was determined on the Abbott m2000TM platform, targeting the Pol gene. The detection threshold was greater than or equal to 40 copies/mL. Data analysis was performed using Excel and SPSS version 20 softwares. Results: A total of 504 people were selected, with an average age of 48±11 years and a predominance of women (70.8%). Antiretroviral treatment had been initiated at clinical stage 1 in over 80% of participants. The TDF/3TC/EFV regimen prior to initiation of Dolutegravir was used in 93.5% of cases. Mean weight after initiation of treatment was 75.9 kg. People with a viral load <40 copies/ml before starting Dolutegravir therapy accounted for 332 (65.9%) of cases, compared with 91.1% six months after starting treatment. Weight (>75kg) (95% CI, OR=1.112-2.381, p=0.012) and non-adherence (95% CI, OR=2.790-25.613, p=0.001) were considered factors associated with viral load variation. Conclusion: The ARV protocol comprising two nucleoside reverse transcriptase inhibitors and Dolutegravir improves virological response in people living with HIV at all clinical stages.

HIV viral load dolutegravir Douala

References (8)

  1. 1 Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS) [DOI]
  2. 2 Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS [DOI]
  3. 3 Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1 [DOI]
  4. 4 Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials [DOI]
  5. 5 Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial [DOI]
  6. 6 Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform [DOI]
  7. 7 Immunovirological discordance among female sex workers who start antiretroviral therapy in Burkina Faso [DOI]
  8. 8 Factors Associated with HIV and Vulnerability Contexts for Women in Brazil [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

24

Page views

0

PDF downloads

4

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.